



UK Health
Security
Agency

UK Standards for Microbiology Investigations

X and V factor test



Acknowledgments

UK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of UKHSA working in partnership with the partner organisations whose logos are displayed below and listed on [the UK SMI website](#). UK SMIs are developed, reviewed and revised by various working groups which are overseen by a [steering committee](#).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

UK SMIs are produced in association with:



Displayed logos correct as of December 2024

Contents

| | |
|----------------------------------------------------------------------|-----------|
| Acknowledgments | 2 |
| Contents | 3 |
| Amendment table | 4 |
| 1 General information | 5 |
| 2 Scientific information | 5 |
| 3 Scope of document | 5 |
| 4 Introduction | 5 |
| 5 Technical information/limitations | 5 |
| 6 Safety considerations | 6 |
| 7 Reagents and equipment | 7 |
| 8 Quality control organisms | 7 |
| 9 Procedure and results | 7 |
| 10 Algorithm: X and V factor test | 9 |
| 11 Table: Summary of X and V factor test results | 10 |
| References | 11 |

Amendment table

Each UK SMI document has an individual record of amendments. The amendments are listed on this page. The amendment history is available from standards@ukhsa.gov.uk.

Any alterations to this document should be controlled in accordance with the local document control process.

| | |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment number/date | 11/12.03.25 |
| Issue number discarded | 4.1 |
| Insert issue number | 4.2 |
| Section(s) involved | Amendment |
| Whole document. | <p>This is an administrative point change.</p> <p>The content of this UK SMI document has not changed.</p> <p>The last scientific and clinical review was conducted on 08/05/2019.</p> <p>Hyperlinks throughout document updated to Royal College of Pathologists website.</p> <p>Public Health England replaced with UK Health Security Agency throughout the document, including the updated Royal Coat of Arms</p> <p>Partner organisation logos updated.</p> <p>Broken links to devolved administrations replaced.</p> <p>References to NICE accreditation removed.</p> |

| | |
|----------------------------|----------------------------------------------------------------------------------------|
| Amendment number/date | 10/16.10.24 |
| Issue number discarded | 4 |
| Insert issue number | 4.1 |
| Section(s) involved | Amendment |
| Whole document. | <p>Document transferred to new template.</p> <p>Minor changes to text for clarity.</p> |

X and V factor test

| | |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------|
| | Table of results has moved to section 10 |
| Technical information/limitations | Correction made for X and V factor test to be performed using a minimal nutrient agar, such as basic nutrient agar |

| | |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Amendment number/date | 9/08.05.19 |
| Issue number discarded | 3 |
| Insert issue number | 4 |
| Anticipated next review date* | 08.05.22 |
| Section(s) involved | Amendment |
| Whole document. | Document updated. References updated with grades. Flowchart updated to include commercial alternatives. |
| Quality control organisms. | Alternative bacterial NCTC strain (NCTC 12975) tested and validated for this test and EUCAST susceptibility tests. |

*Reviews can be extended up to 5 years where appropriate

1 General information

[View general information](#) related to UK SMIs.

2 Scientific information

[View scientific information](#) related to UK SMIs.

3 Scope of document

This UK Standards for Microbiology Investigations (UK SMI) document describes the differentiation of *Haemophilus* species by the X and V test.

This procedure is not recommended to be the sole criterion for species identification because similarities exist in growth factor requirements of *Haemophilus* species. Test results of other biochemical tests and even molecular analysis may be required for complete identification

This UK SMI should be used in conjunction with other UK SMIs.

4 Introduction

Species of the genus *Haemophilus* require either or both of two factors X and V for growth and can be used to differentiate the species. Both factors are present in blood.

X factor comprises protoporphyrin IX, also called haemin or other iron-containing porphyrins. These are required for growth because X-dependent strains are unable to convert d-aminolaevulinic acid to protoporphyrin. They are heat stable.

V factor comprises nicotinamide adenine dinucleotide (NAD) or nicotinamide adenine dinucleotide phosphate (NADP). They are heat labile (1).

The factors are incorporated in filter paper discs which are placed on a blood free medium previously inoculated with the organism under test. After incubation, the presence or absence of growth around the discs is recorded. The presence of growth around the disc but not elsewhere on the plate indicates a requirement for that particular factor.

5 Technical information/limitations

Erroneous results

V factor diffuses more readily than X factor. V factor may diffuse towards the X factor disc, leading to growth seemingly being due to X factor rather than V (1). To reduce this, place the discs at least 1 cm apart from each other.

Quality control of commercial identification kits

Commercial manufacturers of X and V factor discs do not specify the concentration of the factors. Acceptance of a batch of discs should be based on an 'in use' performance test with a range of *Haemophilus* species rather than an assay of content.

Each batch or shipment of XV factor discs should be checked with a positive control, and the X factor and V factor discs are tested with both known positive and negative controls before routine use in the laboratory to ensure quality control.

Agar media

The X and V factor test should be performed using a minimal nutrient agar, such as basic nutrient agar, but for which the X and V discs have been validated. Any trace of the X or V factors in the medium could influence the results usually identifying *H. influenzae* as *H. parainfluenzae*.

Manufacturers' instructions should be followed when performing this test.

More accurate results are obtained with the porphyrin synthesis test. Please refer to [UK SMI TP 29 – porphyrin test](#).

The swab used for setting up the plate for X and V factors can also be used for setting up antibiotic plates providing the X and V factors are set up first.

Incubation

The X and V factor tests could sometimes give false V dependent results if incubated in CO₂ (2).

Issues with the HACEK group of organisms (apart from *Haemophilus* species)

Eikenella corrodens are X-dependent as they exhibit growth around the X disc when tested, which is a useful diagnostic test. The other organisms may be X and V-dependent or may require only either X or V factor (1).

6 Safety considerations

The section covers specific safety considerations (3-21) related to this UK SMI, and should be read in conjunction with the general [safety considerations](#).

Haemophilus influenzae is a Hazard Group 2 organism and in some cases the nature of the work may dictate full Containment Level 3 conditions. All laboratories should handle specimens as if potentially high risk.

H. influenzae can cause serious invasive disease, especially in young children. Invasive disease is usually caused by encapsulated strains of the organism.

Laboratory acquired infections have been reported (22). The organism infects primarily by the respiratory route (inhalation), autoinoculation or ingestion in laboratory workers (23).

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet. Eye protection must be used where there is a known or potential risk of exposure to splashes.

Refer to current guidance on the safe handling of all organisms and reagents documented in this UK SMI.

The above guidance should be supplemented with local COSHH and risk assessments.

7 Reagents and equipment

- Normal saline or distilled water
- Sterile swabs
- Test agar plate, follow manufacturers' instructions
- Commercially available discs/strips impregnated with X, V and XV factors
- Bacteriological straight wire/loop or disposable alternative

8 Quality control organisms

X and V factor

Haemophilus influenzae NCTC 11931 or NCTC 12975

V factor only

Haemophilus parainfluenzae NCTC 10665

X factor only

Haemophilus haemoglobinophilus NCTC 8540

Note: These strains have been validated by NCTC to give this result.


9 Procedure and results

Procedure for X and V factor test method (1,2):

- make a light suspension of the test organism by touching one or more morphologically similar colonies with a straight wire and emulsifying in normal saline or distilled water
- soak a swab in the suspension and spread evenly across the entire surface of a test agar plate. This allows for maximum growth
- allow a few minutes for agar surface to dry
- place X, V and XV discs on the agar surface in area of inoculum. Ensure the discs are a minimum of 1cm apart in an equilateral triangle configuration (to prevent diffusion from the discs giving false results) or follow manufacturer's instructions
- gently press down on discs so that they adhere to agar surface


X and V factor test

- incubate in 3-5% CO₂ at 35-37°C overnight
- examine the plates in a good light source for visible growth between and around the discs. Interpret the test agar plates according to the table below




H. influenzae

(Growth around XV disc only)



H. parainfluenzae

(Growth around V and XV discs)



H. haemoglobinophilus

(Growth around X and XV discs)

Interpretation

Organisms that require only X factor will grow only around the X and XV factor discs.


Organisms that require only V factor will grow only around the V and the XV factor discs.

If both X and V factors are required, the organism will grow only around the XV factor disc.

For a summary of X, V and XV factor results, please see section 10.

10 Algorithm: X and V factor test

An accessible text description of this flowchart is provided with this document



Note:

| | |
|----------------|-------------------------------------------------------|
| X and V factor | <i>Haemophilus influenzae</i> NCTC 11931 or NCTC12975 |
| V factor only | <i>Haemophilus parainfluenzae</i> NCTC 10665 |
| X factor only | <i>Haemophilus haemoglobinophilus</i> NCTC 8540 |

Please note that sometimes the X and V factor tests could give false V dependent results if incubated in CO₂.

11 Table: Summary of X and V factor test results

| <i>Haemophilus</i> species | Growth around discs | | |
|--------------------------------|---------------------|---|----|
| | X | V | XV |
| <i>H. influenzae</i> | - | - | + |
| <i>H. parainfluenzae</i> | - | + | + |
| <i>H. haemoglobinophilus</i> | + | - | + |
| <i>H. aegyptius</i> * | - | - | + |
| <i>H. haemolyticus</i> | - | - | + |
| <i>H. pittmaniae</i> | - | + | + |
| <i>H. parahaemolyticus</i> | - | + | + |
| <i>H. paraphrohaemolyticus</i> | - | + | + |
| <i>H. ducreyi</i> | + | - | + |
| <i>H. sputorum</i> | - | + | + |

**H. aegyptius* is indistinguishable from *H. influenzae* biotype III in normal laboratory tests.
Adapted from MacFaddin (1)

References

An explanation of the reference assessment used is available in the [scientific information section](#).

1. MacFaddin JF. X and V Factors. Biochemical Tests for Identification of Medical Bacteria. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2000. pages. 451-3. **B, III**
2. Jones AM. Haemophilus influenzae and H. parainfluenzae: the influence of media and CO² on differentiation using X, V and XV discs. MedLab Sci 1982: volume 39, issue 2, pages 189-91. **B, III**
3. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive 2013. pages 1-35. **A, VI**
4. Advisory Committee on Dangerous Pathogens. Biological Agents: Managing the Risks in Laboratories and Healthcare Premises. Appendix 1.2 Transport of Infectious Substances - Revision. Health and Safety Executive 2008. **A, VI**
5. Advisory Committee on Dangerous Pathogens. Biological agents: Managing the risks in laboratories and healthcare premises. Health and Safety Executive 2005. **A, VI**
6. Advisory Committee on Dangerous Pathogens. Infections at work: Controlling the risks. Her Majesty's Stationery Office 2003. **A, VI**
7. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets 2000. **A, VI**
8. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 2005. pages 1-14. **A, VI**
9. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. MMWR Surveill Summ 2012: volume 61, pages 1-102. **B, V**
10. Department for Transport. Transport of Infectious Substances, 2011 Revision 5. 2011. **A, VI**
11. Department of Health. Transport of Infectious Substances. Best Practice Guidance for Microbiology Laboratories. Department of Health. pages 1-13. 2007. **A, VI** 01 June 2007

12. Department of Health. Health Protection Legislation (England) Guidance. pages 1-112. 2010. **A, VI**
13. European Parliament. UK Standards for Microbiology Investigations (UK SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU *in vitro* Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes". 1998. **A, VI**
14. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved Code of Practice and guidance L5 (sixth edition). HSE Books,. 2013. **A, VI**
15. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 2009. **A, VI**
16. Health and Safety Executive. Five Steps to Risk Assessment: A Step by Step Guide to a Safer and Healthier Workplace. HSE Books,. 2002. **A, VI**
17. Health and Safety Executive. A Guide to Risk Assessment Requirements: Common Provisions in Health and Safety Law. HSE Books,. 2002. **A, VI**
18. Health Services Advisory Committee. Safe Working and the Prevention of Infection in Clinical Laboratories and Similar Facilities. HSE Books 2003. **A, VI**
19. Home Office. Anti-terrorism, Crime and Security Act. 2001. **A, VI**
20. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices 1998. pages 1-37. **A, VI**
21. World Health Organization. Guidance on regulations for the Transport of Infectious Substances 2017-2018. 2017. **A, VI**
22. Collins CH, Kennedy.D.A. Laboratory acquired infections. In: Woburn MA, editor. Laboratory acquired infection: History, incidence, causes and prevention. 4 ed.; 1999. pages. 1-37. **B, IV**
23. Jacobson JT and others. Infections acquired in clinical laboratories in Utah. Journal of Clinical Microbiology 1985: volume 21, issue 4, pages 486-9.**C, IV**